208 related articles for article (PubMed ID: 35230473)
1. Mammalian target of rapamycin inhibitors for the treatment of astrocytic hamartoma in tuberous sclerosis complex (TSC).
Vorobichik Berar O; Tzadok M; Zloto O; Moroz I; Hecht I; Musika AA; Shlomovitz O; Fabian ID; Vishnevskia Dai V
Graefes Arch Clin Exp Ophthalmol; 2022 Sep; 260(9):3061-3068. PubMed ID: 35230473
[TBL] [Abstract][Full Text] [Related]
2. Long-term efficacy and safety of sirolimus for retinal astrocytic hamartoma associated with tuberous sclerosis complex.
Zhang CX; Xu KF; Long Q; Zhang X; Yang ZK; Dai RP; Zhang ZQ
Front Cell Dev Biol; 2022; 10():973845. PubMed ID: 36467422
[TBL] [Abstract][Full Text] [Related]
3. [The fundus autofluorescence of retinal astrocytic hamartomas in tuberous sclerosis complex].
Zhang CX; Zhang ZQ; Xu KF; Long Q; Yang ZK; Dai RP; Du H; Li DH
Zhonghua Yan Ke Za Zhi; 2020 Mar; 56(3):211-216. PubMed ID: 32187950
[No Abstract] [Full Text] [Related]
4. Clinical features and optical coherence tomography findings of retinal astrocytic hamartomas in Chinese patients with tuberous sclerosis complex.
Zhang C; Xu K; Long Q; Yang Z; Dai R; Du H; Li D; Zhang Z
Graefes Arch Clin Exp Ophthalmol; 2020 Apr; 258(4):887-892. PubMed ID: 31897702
[TBL] [Abstract][Full Text] [Related]
5. Retinal astrocytic hamartoma in tuberous sclerosis complex in an elderly person: a case report.
Qin X; Tao Y; Zhang Z
BMC Ophthalmol; 2018 Dec; 18(1):319. PubMed ID: 30541513
[TBL] [Abstract][Full Text] [Related]
6. Treatment of tuberous sclerosis complex manifestations in children with mTOR inhibitors.
Yeşil Ş; Kurucu B; Hamamcı MB; Yılmaz Ş; Şahin G
Childs Nerv Syst; 2024 Mar; 40(3):831-837. PubMed ID: 37947859
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Aggressive Retinal Astrocytic Hamartoma with Oral Mechanistic Target of Rapamycin Inhibition.
Wu F; McGarrey MP; Geenen KR; Skalet AH; Guillot FH; Wilson JL; Shah AS; Gonzalez E; Thiele EA; Kim IK; Aronow ME
Ophthalmol Retina; 2022 May; 6(5):411-420. PubMed ID: 35007768
[TBL] [Abstract][Full Text] [Related]
8. Short-term safety of mTOR inhibitors in infants and very young children with tuberous sclerosis complex (TSC): Multicentre clinical experience.
Krueger DA; Capal JK; Curatolo P; Devinsky O; Ess K; Tzadok M; Koenig MK; Narayanan V; Ramos F; Jozwiak S; de Vries P; Jansen AC; Wong M; Mowat D; Lawson J; Bruns S; Franz DN;
Eur J Paediatr Neurol; 2018 Nov; 22(6):1066-1073. PubMed ID: 30005812
[TBL] [Abstract][Full Text] [Related]
9. mTOR inhibitors in the pharmacologic management of tuberous sclerosis complex and their potential role in other rare neurodevelopmental disorders.
Franz DN; Capal JK
Orphanet J Rare Dis; 2017 Mar; 12(1):51. PubMed ID: 28288694
[TBL] [Abstract][Full Text] [Related]
10. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
MacKeigan JP; Krueger DA
Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
[TBL] [Abstract][Full Text] [Related]
11. Regression of symptomatic multiple cardiac rhabdomyomas associated with tuberous sclerosis complex in a newborn receiving everolimus.
Doğan V; Yeşil Ş; Kayalı Ş; Beken S; Özgür S; Ertuğrul İ; Bozkurt C; Örün UA; Karademir S
J Trop Pediatr; 2015 Feb; 61(1):74-7. PubMed ID: 25344617
[TBL] [Abstract][Full Text] [Related]
12. Optic coherence tomography appearances of retinal astrocytic hamartoma and systemic features in tuberous sclerosis of Japanese patients.
Kato A; Obana A; Gohto Y; Seto T; Sasano H
Eur J Ophthalmol; 2019 May; 29(3):330-337. PubMed ID: 29991284
[TBL] [Abstract][Full Text] [Related]
13. Analysis of serum lipid parameters predicting lipid metabolic disorders in TSC-AML patients with treatment of mTOR inhibitors.
Wang W; Wang Z; Zhao Y; Wang X; Li H; Zhang Y
J Clin Pharm Ther; 2022 Jul; 47(7):979-985. PubMed ID: 35229896
[TBL] [Abstract][Full Text] [Related]
14. Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy.
Curatolo P
Pediatr Neurol; 2015 Mar; 52(3):281-9. PubMed ID: 25591831
[TBL] [Abstract][Full Text] [Related]
15. Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex.
Cardamone M; Flanagan D; Mowat D; Kennedy SE; Chopra M; Lawson JA
J Pediatr; 2014 May; 164(5):1195-200. PubMed ID: 24518170
[TBL] [Abstract][Full Text] [Related]
16. Refractive Errors, Retinal Findings, and Genotype of Tuberous Sclerosis Complex: A Retrospective Cohort Study.
Ryu S; Kang HC; Lee SC; Byeon SH; Kim SS; Lee CS
Yonsei Med J; 2023 Feb; 64(2):133-138. PubMed ID: 36719021
[TBL] [Abstract][Full Text] [Related]
17. Perfect match: mTOR inhibitors and tuberous sclerosis complex.
Luo C; Ye WR; Shi W; Yin P; Chen C; He YB; Chen MF; Zu XB; Cai Y
Orphanet J Rare Dis; 2022 Mar; 17(1):106. PubMed ID: 35246210
[TBL] [Abstract][Full Text] [Related]
18. Retinal Astrocytic Hamartoma Arises in Nerve Fiber Layer and Shows "Moth-Eaten" Optically Empty Spaces on Optical Coherence Tomography.
Shields CL; Say EAT; Fuller T; Arora S; Samara WA; Shields JA
Ophthalmology; 2016 Aug; 123(8):1809-1816. PubMed ID: 27157148
[TBL] [Abstract][Full Text] [Related]
19. The efficacy of cannabidiol on renal angiomyolipoma and subependymal giant cell tumor volume in tuberous sclerosis complex.
Barnett JR; Grinspoon RA; Harisinghani M; Caruso PA; Thiele EA
J Clin Neurosci; 2020 Jul; 77():85-88. PubMed ID: 32409220
[TBL] [Abstract][Full Text] [Related]
20. Everolimus in immunosuppressive treatment after kidney transplantation in a patient with tuberous sclerosis: case report.
Tarasewicz A; Dębska-Ślizień A; Bułanowski M; Więcek A; Rutkowski B
Transplant Proc; 2014 Oct; 46(8):2912-5. PubMed ID: 25380949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
